Jun 27,2024

South Korea approves first local skin cancer detection AI

LifeSemantics, a Korean digital health company, has received regulatory approval from South Korea's Ministry of Food and Drug Safety for its AI-powered skin cancer diagnosis solution, canofyMD SCAI. Developed through the Doctor Answer 2.0 project, the mobile AI technology uses convolutional neural networks to diagnose skin cancer, including melanoma and carcinoma, via smartphone images. The AI, trained on 6,500 images, showed an 80.9% diagnostic accuracy in clinical trials. LifeSemantics plans to launch the app commercially by year-end and seeks regulatory approvals in Australia and New Zealand.

REGULATORY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 14,2023

Aptar Digital Health and Legit.Health announces new Immuno-Dermatology Partnership

Aptar Digital Health has partnered with Legit.Health to enhance patient experience in immuno-dermatology. The collaboration integrates Legit.Health's AI-based technology into Aptar's digital health platform to better manage and treat skin conditions like atopic dermatitis, psoriasis, and skin cancer. The advanced digital solution aims to aid healthcare professionals in early diagnosis and patients in starting treatment plans sooner, thus improving overall quality of life. Leveraging AI for disease progression monitoring and clinically validated scoring systems like PASI and SCORAD, the partnership ensures patients receive accurate information for effective management.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Mar 20,2024

AI-Based App can Help Physicians Find Skin Melanoma

A study led by Linköping University in Sweden tested a mobile app, Dermalyser (AI Medical Technology, Stockholm, Sweden), using artificial intelligence (AI) to analyze images of skin lesions for diagnosing melanoma in primary care settings. Published in the British Journal of Dermatology, the study revealed promising results, showing the app's high precision in identifying melanoma and distinguishing it from harmless lesions. The app detected all melanomas and missed only one precursor, with a 99.5% probability of accurately identifying non-melanoma lesions. While the app's effectiveness is encouraging, further research is needed to evaluate its real-world utility as a decision support tool. The researchers plan to conduct a larger follow-up study in multiple countries to assess the app's performance in active decision-making scenarios.

CLINICAL STUDY

#mobile app

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 17,2024 TOP STORY

FDA Approves First AI-Powered Skin Cancer Diagnostic Tool

The FDA has approved the DermaSensor, the first AI-powered tool to diagnose skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma, at the point of testing and noninvasively. The DermaSensor is a wireless, handheld device that uses spectroscopy technology to examine lesions at cellular and subcellular levels, then analyze those characteristics using an FDA-cleared algorithm. The device was evaluated in the DERM-SUCCESS study which was led by the Mayo Clinic across 22 study centers and enrolled over 1000 patients. The DermaSensor device demonstrated a 96% sensitivity across all 224 types of skin cancers. Further, negative results from the DermaSensor had a 97% chance of being benign across all skin cancers. A companion clinical utility study also investigated the DermaSensor’s usage with 108 physicians. This study found that the device decreased the number of missed skin cancers by half (18% vs 9%). The FDA previously granted breakthrough device designation to DermaSensor in 2021.

REGULATORY FDA

#connected device

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 27,2023

Skin Cancer Diagnoses Using AI Are as Reliable as those Made by Medical Experts

Artificial intelligence (AI) is already widely used in medical diagnostics. An Austrian-Australian research team led by dermatologist Harald Kittler from MedUni Vienna investigated the extent to which diagnosis and therapy of pigmented skin lesions benefit from it in a realistic clinical scenario. In a study published by The Lancet Digital Health, the team compared the accuracy in diagnosis and therapy recommendation of two different algorithms in smartphone applications with that of doctors. The results show that the AI application generally performs well in diagnosis. However, doctors were clearly superior when it came to treatment decisions.

CLINICAL STUDY

#ai/software

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to SKIN CANCER